Division of Endocrinology and Diabetes, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA.
J Clin Endocrinol Metab. 2011 Dec;96(12):3592-8. doi: 10.1210/jc.2011-1515.
The diagnosis of gestational diabetes mellitus (GDM) identifies patients with a pancreatic β-cell defect. In some patients, the defect is transient or stable, but in most it is progressive, imparting a high risk of diabetes for at least a decade after the index pregnancy. The β-cell defects in GDM can result from many causes, including genetic variants typical of monogenic forms of diabetes and autoimmunity typical of evolving type 1 diabetes. No specific disease-modifying therapies are available for those patients. The majority of women with GDM have clinical characteristics indicating a risk for type 2 diabetes (T2D). Available evidence indicates that T2D can be prevented or delayed by intensive lifestyle modification and by medications, particularly those that ameliorate insulin resistance. Clinical management should include assessment of glucose tolerance in the postpartum period to detect diabetes or assess diabetes risk. Women who don't have diabetes should be advised about their risk and participate in family planning to prevent subsequent pregnancies with undiagnosed hyperglycemia. All patients should be monitored for rising glycemia indicative of progressive β-cell deterioration. We suggest a combination of fasting glucose and glycosylated hemoglobin measurements for this purpose. Monitoring should be initiated at least annually and should be intensified if glycemia is rising and/or impaired. Lifestyle modification is advised to reduce the risk for T2D. Like monitoring, lifestyle modification should be intensified for rising glycemia and/or development of impaired glucose levels. At present, there is insufficient evidence to recommend medications to prevent T2D. Close follow-up and monitoring will allow initiation of pharmacological treatment as soon as diabetes develops. Children of women with GDM are at increased risk for obesity and diabetes. They should receive education, monitoring, and lifestyle advice to minimize obesity and diabetes risk.
妊娠期糖尿病(GDM)的诊断可识别出存在胰腺β细胞缺陷的患者。在一些患者中,这种缺陷是暂时的或稳定的,但在大多数患者中,它是进行性的,在指数妊娠后至少十年内会增加患糖尿病的高风险。GDM 的β细胞缺陷可能由多种原因引起,包括典型的单基因糖尿病的遗传变异和典型的 1 型糖尿病进展的自身免疫。对于这些患者,尚无特定的疾病修正治疗方法。大多数患有 GDM 的女性具有表明发生 2 型糖尿病(T2D)风险的临床特征。现有证据表明,通过强化生活方式改变和药物治疗(特别是那些改善胰岛素抵抗的药物)可以预防或延迟 T2D。临床管理应包括在产后期间评估葡萄糖耐量,以检测糖尿病或评估糖尿病风险。没有糖尿病的女性应告知其风险,并参与家庭计划,以防止随后发生未经诊断的高血糖妊娠。所有患者都应监测血糖升高,以提示β细胞恶化。为此,我们建议结合空腹血糖和糖化血红蛋白测量值进行监测。监测应至少每年进行一次,如果血糖升高和/或受损,应加强监测。建议进行生活方式改变以降低 T2D 的风险。与监测一样,如果血糖升高和/或葡萄糖水平受损,应加强生活方式改变。目前,尚无足够的证据推荐药物预防 T2D。密切随访和监测将允许在糖尿病发生后尽快开始药物治疗。患有 GDM 的女性的孩子患肥胖症和糖尿病的风险增加。他们应该接受教育、监测和生活方式建议,以最大程度地降低肥胖症和糖尿病风险。